The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation

Zhou,Wei; Chen,Ming-Kun; Yu,Hao-Tao; Zhong,Zhi-Hong; Cai,Nan; Chen,Guan-Zhong; Zhang,Ping; Chen,Jia-Jie

doi:10.3892/ijo.2015.3229

The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation

Authors:
- Wei Zhou
- Ming-Kun Chen
- Hao-Tao Yu
- Zhi-Hong Zhong
- Nan Cai
- Guan-Zhong Chen
- Ping Zhang
- Jia-Jie Chen
View Affiliations

Affiliations: Department of Orthopedics, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China, Department of Urology, the Third Affiliated Hospital of Southern Medical University, Guangzhou, P.R. China, Vaccine Research Institute of Sun Yat-sen University, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, P.R. China
Published online on: November 4, 2015 https://doi.org/10.3892/ijo.2015.3229
Pages: 322-328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Currently, drug discovery and development for clinical treatment of prostate cancer has received increased attention, specifically the STAT3 inhibitor. Our previous study reported that the neuroleptic drug pimozide had antitumor activity against hepatocellular carcinoma cells or stem-like cells through suppressing the STAT3 activity. In the present study we demonstrate that pimozide inhibits cell growth and cellular STAT3 activation in prostate cancer cells. Our results showed that pimozide inhibited prostate cancer cell proliferation in a dose- and time-dependent manner by inducing G1 phase cell cycle arrest, downregulated the ability of colony formation and sphere forming, as well as suppressed cells migration in both DU145 and LNCaP cells. Surprisingly, pimozide reduced the basal expression of phosphorylation STAT3 at tyrosine 705 and reversed the expression of phosphorylation of STAT3 induced by IL-6 addition, suggesting that pimozide can suppress cellular STAT3 activation. Thus, the antipsychotic agent pimozide may be a potential and novel therapeutic for patients with advanced prostate cancer.

View Figures

View References

1	Boguski MS, Mandl KD and Sukhatme VP: Drug discovery. Repurposing with a difference. Science. 324:1394–1395. 2009. View Article : Google Scholar : PubMed/NCBI
2	Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA: Metformin: Multi-faceted protection against cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon JH, Moon JO, Chung HY, Kim GY, Choi YH, Copple BL, et al: Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int J Oncol. 40:1298–1304. 2012.
4	Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, et al: Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 3:1112–1123. 2012. View Article : Google Scholar : PubMed/NCBI
5	Bashir MN: Epidemiology of prostate cancer. Asian Pac J Cancer Prev. 16:5137–5141. 2015. View Article : Google Scholar : PubMed/NCBI
6	Karantanos T, Corn PG and Thompson TC: Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 32:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
7	Barton BE, Karras JG, Murphy TF, Barton A and Huang HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther. 3:11–20. 2004. View Article : Google Scholar : PubMed/NCBI
8	Ni Z, Lou W, Leman ES and Gao AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 60:1225–1228. 2000.PubMed/NCBI
9	Bishop JL, Thaper D and Zoubeidi A: The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers (Basel). 6:829–859. 2014. View Article : Google Scholar
10	Egolf A and Coffey BJ: Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs Today (Barc). 50:159–179. 2014. View Article : Google Scholar
11	Taub RN and Baker MA: Treatment of metastatic malignant melanoma with pimozide. Lancet. 1:6051979. View Article : Google Scholar : PubMed/NCBI
12	Strobl JS, Kirkwood KL, Lantz TK, Lewine MA, Peterson VA and Worley JF III: Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res. 50:5399–5405. 1990.PubMed/NCBI
13	Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, et al: The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 117:3421–3429. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, et al: The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations. Genes Cancer. 3:503–511. 2012. View Article : Google Scholar : PubMed/NCBI
15	Strobl JS, Melkoumian Z, Peterson VA and Hylton H: The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide. Breast Cancer Res Treat. 51:83–95. 1998. View Article : Google Scholar
16	Chen JJ, Cai N, Chen GZ, Jia CC, Qiu DB, Du C, Liu W, Yang Y, Long ZJ and Zhang Q: The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma. Oncotarget. May 27–2015.Epub ahead of print.
17	Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: Cytokine network, tumorigenic and metastatic properties. PLoS One. 3:e30772008. View Article : Google Scholar : PubMed/NCBI
18	Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
19	Shodeinde AL and Barton BE: Potential use of STAT3 inhibitors in targeted prostate cancer therapy: Future prospects. Onco Targets Ther. 5:119–125. 2012.PubMed/NCBI
20	Guo Y, Xu F, Lu T, Duan Z and Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 38:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hodge DR, Hurt EM and Farrar WL: The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
22	Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, et al: High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74:1272–1283. 2014. View Article : Google Scholar
23	Lorenzo CR and Koo J: Pimozide in dermatologic practice: A comprehensive review. Am J Clin Dermatol. 5:339–349. 2004. View Article : Google Scholar : PubMed/NCBI
24	Seeman P: Atypical antipsychotics: Mechanism of action. Can J Psychiatry. 47:27–38. 2002.PubMed/NCBI
25	Muscat R, Sampson D and Willner P: Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry. 28:223–230. 1990. View Article : Google Scholar : PubMed/NCBI
26	Chen X, Ji ZL and Chen YZ: TTD: Therapeutic target database. Nucleic Acids Res. 30:412–415. 2002. View Article : Google Scholar :
27	Jing N and Tweardy DJ: Targeting Stat3 in cancer therapy. Anticancer Drugs. 16:601–607. 2005. View Article : Google Scholar : PubMed/NCBI
28	Wendt MK, Balanis N, Carlin CR and Schiemann WP: STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT. 3:e289752014.PubMed/NCBI
29	Teng Y, Ross JL and Cowell JK: The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT. 3:e280862014.PubMed/NCBI
30	Al Zaid Siddiquee K and Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 18:254–267. 2008. View Article : Google Scholar : PubMed/NCBI
31	Wang X, Crowe PJ, Goldstein D and Yang JL: STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (Review). Int J Oncol. 41:1181–1191. 2012.PubMed/NCBI
32	Yu H, Kortylewski M and Pardoll D: Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar
33	Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S and Sozen S: Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro. Oncol Lett. 7:755–763. 2014.PubMed/NCBI
34	Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, Cao Y, Bai J, Ma D, Zhou J, et al: Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget. 5:8416–8428. 2014. View Article : Google Scholar : PubMed/NCBI
35	Zhao M, Jiang B and Gao FH: Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem. 18:4012–4018. 2011. View Article : Google Scholar : PubMed/NCBI
36	Mankan AK and Greten FR: Inhibiting signal transducer and activator of transcription 3: Rationality and rationale design of inhibitors. Expert Opin Investig Drugs. 20:1263–1275. 2011. View Article : Google Scholar : PubMed/NCBI
37	Nelson EA, Sharma SV, Settleman J and Frank DA: A chemical biology approach to developing STAT inhibitors: Molecular strategies for accelerating clinical translation. Oncotarget. 2:518–524. 2011. View Article : Google Scholar : PubMed/NCBI